InvestorsHub Logo
Post# of 252321
Next 10
Followers 75
Posts 4673
Boards Moderated 0
Alias Born 09/06/2003

Re: oc631 post# 117645

Tuesday, 04/05/2011 3:34:28 PM

Tuesday, April 05, 2011 3:34:28 PM

Post# of 252321
VRUS

As far as the measuring the drop in viral load, you do the math



From abstract: Monotherapy PSI-938, monotherapy PSI-7977, or combination PSI-938+PSI-7977 provided profound and consistent reductions in HCV RNA with HCV RNA < LOD (15 IU/mL) as early as day 3 of the monotherapy phase.

This does not say that all patients ended up with HCV RNA< LOD. The very fact that it does not say it implies that, in fact, some patients from each cohort did not make it under LOD by day 14.

They didn't give any data on breakthroughs because there weren't any



Although I tend to actually believe this, nonetheless a question: do you have a source for this?

So you are assuming both that if you add a 3rd DAA you can both improve SVR and(!!!) shorten duration of treatment. That seems a leap too far to me. Go back and read my posts.



I did. You asserted a belief that a 3 drug VRUS combo would avoid the breakthroughs seen in BMY's 2 DAA trial in nulls and that it wouldn't need 24 weeks.



Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.